

## Somatropin (humatrope, genotropin, norditropin, nutropin, omnitrope, saizen)

### PART 1 – Instructions

Please use this form to submit your application for Somatropin to Canada Life.

1. Complete parts 2 to 7 in full and have your attending physician or nurse practitioner complete parts 8 to 9.
2. Please apply for coverage through the appropriate provincial/territorial health program before submitting this application to Canada Life (if applicable).
3. Send to Canada Life. See part 10.

Please note that physician's fees for providing medical information are not covered under the Public Service Health Care Plan (PSHCP).

All forms under the Public Service Health Care Plan (PSHCP) must be submitted through the plan member. We may disclose personal information about claims with your employer, your service provider, and/or a person acting on your behalf when necessary to confirm eligibility and to mutually manage your assessment.

### PART 2 – Plan member information - You must complete this section fully. If you are unsure of your plan or certificate number, please see your Public Service Health Care Plan (PSHCP) benefit card, the Canada Life PSHCP Member Service website or Part 10 for our contact information.

Plan name <b>Public Service Health Care Plan</b>	Plan number	Plan member certificate number	
<b>Plan member name</b>			
First name	Last name		
<b>Plan member address</b>			
Number and street	City or town	Province/Territory/State	Postal/Zip Code
Country	<b>Date of birth</b>	Day	Month
		Year	

### PART 3 – Patient information

Patient name		Patient's relationship to plan member			Patient's date of birth			If dependant child is between 21 and 25 years old, are they a full-time student?	
First name	Last name	Self	Spouse or common-law partner	Dependant child	Day	Month	Year	Yes	No
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>				<input type="checkbox"/>	<input type="checkbox"/>

1. Is the patient currently on or previously been on this drug?  Yes  No

If "Yes", please answer the questions below.

a. Indicate the date you started this medication.  Day  Month  Year

b. Coverage provided by: \_\_\_\_\_  
(if coverage was not provided by Canada Life, please provide a pharmacy print-out showing purchase of this drug)

2. Has the patient enrolled in the Patient Support Program for this drug?  Yes  No

If "Yes", please provide the following information: Patient Support Program ID number: \_\_\_\_\_

Patient Support Program contact name: \_\_\_\_\_ Phone number: \_\_\_\_\_

### PART 4 – Coordination of benefits - Complete this section to indicate whether the patient has benefit coverage under any other plan.

1. Does the patient have prescription drug coverage under any other benefit plan?  Yes  No

If "Yes", please answer the questions below.

2. Name of the insurance company? \_\_\_\_\_

3. Is the other plan with Canada Life?  Yes  No

If "Yes", please provide: Canada Life plan number \_\_\_\_\_ Certificate number \_\_\_\_\_

Name of plan member \_\_\_\_\_ Relationship to patient \_\_\_\_\_

Other insurance plan member's signature of authorization: X \_\_\_\_\_

Provide details and attach documentation of your other insurance company's acceptance or denial of this drug: \_\_\_\_\_

**Somatropin (humatrope, genotropin, norditropin, nutropin, omnitrope, saizen)**

**PART 5 – Provincial or territorial coverage**

1. Does the patient have coverage under a provincial or territorial program or from any other source?  Yes  No

If "Yes", name of program or other source: \_\_\_\_\_

Provide details and attach documentation of the province or territory's acceptance or denial of this drug:  
\_\_\_\_\_

**PART 6 – Privacy**

*Canada Life recognizes and respects the importance of privacy. Personal information collected is used for the purposes of assessing eligibility for this drug and for administering the group benefits plan. For a copy of our Privacy Guidelines, or if you have questions about Canada Life's personal information policies and practices (including with respect to service providers), refer to [canadalife.com](http://canadalife.com) or write to Canada Life's Chief Compliance Officer. Please refer to the [PSHCP Privacy Statement \(canada.ca/en/treasury-board-secretariat/services/benefit-plans/health-care-plan/public-service-health-care-plan-privacy-statement-september-2009.html\)](http://canada.ca/en/treasury-board-secretariat/services/benefit-plans/health-care-plan/public-service-health-care-plan-privacy-statement-september-2009.html) for further information on how your privacy is protected. Where there is a difference between the [Privacy Act \(//laws-lois.justice.gc.ca/eng/acts/P-21/\)](http://laws-lois.justice.gc.ca/eng/acts/P-21/) and the PSHCP Privacy Statement and Canada Life's Privacy guidelines, Canada Life will apply the most stringent requirements.*

**PART 7 – Confirmation, authorization and signature**

*I authorize Canada Life, any healthcare or dentalcare provider, my plan sponsor, the Federal PSHCP Administration Authority, other insurance or reinsurance companies, administrators of government benefits or other benefits programs, other organizations or service providers working with Canada Life located within or outside Canada, to exchange personal information when necessary for these purposes. I understand that personal information may be subject to disclosure to those authorized under applicable law within or outside Canada.*

I acknowledge that the personal information is needed to assess eligibility for this drug and to administer the group benefits plan. I acknowledge that providing consent will help Canada Life to assess my claim and that refusing to consent may result in delay or denial of my claim. This consent may be revoked by me at any time by sending written instruction to that effect.

I also consent to the use of my personal information for Canada Life and its affiliates' internal data management and analytics purposes.

If the patient is a person other than myself, I confirm that the patient has given their consent to provide their personal information and for Canada Life to use and disclose it as set out above.

In accordance with the [Positive Enrolment Authorization and Declaration \(welcome.canadalife.com/pshcp/review-authorizations-and-declarations.html\)](http://welcome.canadalife.com/pshcp/review-authorizations-and-declarations.html) accepted during the completion of Positive Enrolment (refer to your Positive Enrolment Record if you completed Positive Enrolment by paper), I agree to the collection, use and disclosure of personal information as set out in the Privacy section, Canada Life's Privacy guidelines and the PSHCP Privacy Statement.

**I certify that the information given on this claim form is true, correct and complete to the best of my knowledge. Failure to provide true, correct and complete information on this form could result in revocation of any approval decision, a requirement to repay paid claims or other appropriate action.**

Plan member signature X \_\_\_\_\_

Date

**Somatropin (humatrope, genotropin, norditropin, nutropin, omnitrope, saizen)**

**PART 8 – Patient medical information - To be completed by the attending physician or nurse practitioner.**

Attach extra information if necessary. **GENETIC TEST RESULTS ARE NOT REQUIRED**

1. Prescribed drug, dosage and frequency requested:

- Humatrope             Nutropin
- Genotropin            Omnitrope
- Norditropin           Saizen

Prescribed dosage and frequency: \_\_\_\_\_

Patient's weight: \_\_\_\_\_ kg (for weight-based dosing) Date determined:

2. Health Canada Indication (include date of initial diagnosis):

- Growth Hormone Deficiency
- Turner's Syndrome
- Idiopathic Short Stature (Nutropin or Saizen only)
- Prader-Willi Syndrome (Genotropin only)
- Short Stature Homeobox-containing Gene (SHOX) Deficiency (Humatrope only)
- Short Stature – Noonan Syndrome (Norditropin or Norditropin Nordiflex only)
- Small for Gestational Age (Humatrope, Genotropin, Norditropin, Norditropin Nordiflex, Omnitrope, or Saizen)
- Chronic Renal Failure (Nutropin or Saizen only)

Complete questions 1–6 and Patient medical information.

Other (approved by Health Canada): \_\_\_\_\_

Complete questions 1–6 and Other condition (Health Canada approved).

3. What is the anticipated duration of treatment with this drug? \_\_\_\_\_

4. Where will treatment be administered?  Home  Physician's office  Private clinic  Hospital in-patient  Hospital out-patient

5. Please provide medical rationale why this drug has been prescribed instead of an alternate drug with an approved indication for this condition. Genetic test results are not required.

\_\_\_\_\_

6. Drug and treatment history – **must be completed for every request.** If coverage for these drugs was not provided by the PSHCP, please submit a pharmacy printout for the last 12 months.

Prescription drug(s) and treatment(s) past and present	Dosing regimen	Start date (mmm-dd-yyyy)	End date (mmm-dd-yyyy)	Clinical results/outcome
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____

**Somatropin (humatrope, genotropin, norditropin, nutropin, omnitrope, saizen)**

**PART 8 – Patient medical information, continued - To be completed by the attending physician or nurse practitioner.**

**Growth Hormone Deficiency – Adult – Genetic test results are not required**

Does the patient have a diagnosis of adult growth hormone deficiency?  Yes  No

**Submit copies of growth hormone stimulation test results and/or serum inulin-like growth factor-1 (IGF-1) concentrations.**

**Growth Hormone Deficiency – Pediatric – Genetic test results are not required**

Is the patient experiencing growth failure due to an inadequate secretion of endogenous growth hormone (Growth Hormone Deficiency)?  Yes  No

Have other causes of short stature been excluded?  Yes  No

Are the patient's epiphyses closed?  Yes  No

**Turner Syndrome – Genetic test results are not required**

Are patient's epiphyses closed?  Yes  No

**Renewal request**

Are patient's epiphyses closed?  Yes  No

Has patient demonstrated positive response to growth hormone treatment?  Yes  No

**Idiopathic Short Stature – Humatrope, Genotropin, or Omnitrope ONLY**

Have other causes of short stature been excluded?  Yes  No

Are patient's epiphyses closed?  Yes  No

Birth weight: \_\_\_\_\_ kg

Height standard deviation score (SDS) in last 12 months: \_\_\_\_\_

Parental heights:

1. \_\_\_\_\_ cm

2. \_\_\_\_\_ cm

**Submit recent copies of growth chart.**

**Prader-Willi Syndrome – Genotropin ONLY – Genetic test results are not required**

Are patient's epiphyses closed?  Yes  No

Therapy will be used to (select one of the following):

Treat growth failure defined as height velocity Z-score <-1.88

To improve body composition in children

**Renewal request**

Are patient's epiphyses closed?  Yes  No

Has patient demonstrated positive response to growth hormone treatment?  Yes  No

**Short Stature Homeobox-containing Gene (SHOX) Deficiency – Humatrope ONLY – Genetic test results are not required**

Are patient's epiphyses closed?  Yes  No

**Short Stature – Noonan Syndrome – Norditropin and Norditropin Nordiflex ONLY**

Are the patient's epiphyses closed?  Yes  No

Is the patient's height standard deviation score (SDS) < -2?  Yes  No

**Somatropin (humatrope, genotropin, norditropin, nutropin, omnitrope, saizen)**

**PART 8 – Patient medical information, continued - To be completed by the attending physician or nurse practitioner.**

**Small for Gestational Age – Nutropin NOT eligible**

Are patient's epiphyses closed?  Yes  No  
 Was the patient's weight and/or length at birth < -2 standard deviations below the mean for gestational age?  Yes  No  
 Is the patient experiencing current growth failure (current height standard deviation score < -2)?  Yes  No  
 Did the patient fail to achieve catch-up growth (height velocity standard deviation score < 0 in the last year) by 2 - 4 years of age or later?  Yes  No

**Chronic Renal Failure – Nutropin or Saizen ONLY**

Are patient's epiphyses closed?  Yes  No  
 Is patient's eGFR < 75 mL/min/1.73m<sup>2</sup>?  Yes  No  
 There is evidence of growth failure defined as:  
 Height a velocity Z-score < -1.88  
 Height velocity for age < 3<sup>rd</sup> percentile  
 None of the above apply

**Other condition (Health Canada approved)**

Please provide any relevant information related to the disease and attach supporting documentation.

**PART 9 – Attending physician's or nurse practitioner's information, confirmation, and signature**

I certify that the information given on this claim form is true, correct and complete to the best of my knowledge.

**Physician or nurse practitioner's name**

Name and designation

Specialty

Registration number

**Physician or nurse practitioner's address**

Number and street

City or town

Province/Territory/State

Postal/Zip Code

Telephone number (including area code)

Fax number (including area code)

Signature X \_\_\_\_\_

Date Day \_\_\_\_\_ Month \_\_\_\_\_ Year \_\_\_\_\_

**PART 10 – Submitting your application**

Please send the completed form to:

**MAIL**  
 Drug Claims Management  
 The Canada Life Assurance Company  
 PO Box 6000 Winnipeg MB R3C 3A5

**FAX**  
 Drug Claims Management  
 1-204-946-7664

**EMAIL**  
[cldrug.services@canadalife.com](mailto:cldrug.services@canadalife.com)

**Questions?**

Call toll free 1-855-415-4414  
 Monday to Friday from 8 am to 5 pm, your local time or sign in to your account on the Canada Life PSHCP Member Services website at [canadalife.com/pshcp](http://canadalife.com/pshcp) and go to the Contact Us page.



**Deaf or hard of hearing and require access to a telecommunications relay service?**

Please contact us:  
 TTY to Voice: 711 • Voice to TTY: 1-800-855-0511